Related Experiment Videos

[Lp(a) and the cardiovascular risk in dyslipidemia subjects]

L Arsenio1, F Cioni, G G Japichino

  • 1Centro per lo Studio e la Terapia delle Dislipidemie, Azienda Ospedaliera, Parma.

Acta Bio-Medica De L'Ateneo Parmense : Organo Della Societa Di Medicina E Scienze Naturali Di Parma
|September 30, 1999
PubMed

Insights

Elevated levels of lipoprotein(a) (Lp(a)) are linked to coronary heart disease (CHD) but not peripheral vascular disease (PVD) in dyslipidaemic patients. This finding highlights Lp(a) as a significant risk factor for heart disease.

Area of Science:

  • Cardiovascular Medicine
  • Clinical Biochemistry
  • Lipidology

Context:

  • Dyslipidaemic patients present complex cardiovascular risk profiles.
  • Lipoprotein(a) [Lp(a)] is an emerging independent risk factor for atherosclerotic diseases.
  • Understanding Lp(a) associations is crucial for risk stratification.

Purpose:

  • To investigate the correlation between plasma Lp(a) levels and peripheral vascular disease (PVD) and/or coronary heart disease (CHD).
  • To assess Lp(a) levels in relation to stenotic lesions in carotid and femoral arteries and ECG signs of coronary ischemia.

Summary:

  • Plasma Lp(a) levels were measured in 20 dyslipidaemic patients.
  • No significant difference in Lp(a) was found between patients with and without carotid/femoral artery stenotic lesions.
  • Lp(a) levels were significantly higher in patients with ECG-diagnosed coronary ischemic heart disease compared to those with normal ECGs.

Impact:

  • Confirms Lp(a) as a significant risk factor specifically for coronary heart disease in dyslipidaemic individuals.
  • Suggests Lp(a) may not be a primary indicator for peripheral vascular disease in this cohort.
  • Informs clinical practice regarding cardiovascular risk assessment and management in dyslipidaemia.

Related Concept Videos